TEL AVIV, Israel, Nov. 7, 2017 /PRNewswire/ -- Josh Blacher,
Chief Financial Officer of Therapix Biosciences Ltd. (Nasdaq: TRPX)
("Therapix" or the "Company"), a specialty, clinical-stage
pharmaceutical company focusing on the development of
cannabinoid-based treatments, will be presenting at the Biotech
& Money Inv€$tival Showcase on November
14, 2017 and attending the Jefferies Healthcare Conferences
on November 15-16, 2017, in
London. In exclusive partnership
with Jefferies LLC, the Inv€$tival Showcase spans four tracks and
will feature the most exciting companies across seven key
sub-sectors within life sciences.
-
Event: Biotech
& Money Inv€$tival Showcase
-
Date: Tuesday,
November 14, 2017
- Presentation Time: 4:15PM
CET
-
Location:
The Hilton Waldorf, Aldwych, London
-
Event: Jefferies
Healthcare Conference
- Date:
November 15-16, 2017
-
Location:
The Hilton Waldorf, Aldwych, London
Mr. Blacher's presentation at the Biotech & Money Inv€$tival
Showcase on November 14 will be
webcast live and will remain available for 90 days following the
presentation. To access the webcast, please visit the Events tab of
the Investor Relations section of the Therapix website at
www.therapixbio.com.
About Therapix Biosciences:
Therapix Biosciences Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists. Our focus is creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the company is currently engaged
in two internal drug development programs based on repurposing an
FDA approved synthetic cannabinoid (dronabinol): THX-110 targets
the treatment of the symptoms of Tourette syndrome; and THX-130
targets the high-value and under-served market of mild cognitive
impairments and Traumatic Brain Injury (TBI).
Please visit our website for more information at
www.therapixbio.com.
Forward-Looking Statements:
This press release contains forward-looking statements about the
Company's expectations, beliefs, and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. Such
forward-looking statements used in this press release include,
among other things, references to the clinical and commercial
potential of THX-OSA01 for the treatment of Obstructive Sleep
Apnea. Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, our ability to raise the additional funding
needed to continue to pursue our business and product development
plans, the inherent uncertainties associated with developing new
products or technologies, our ability to obtain regulatory approval
for our product candidates, our ability to commercialize our
product candidates, competition in the industry in which we operate
and overall market conditions. Any forward-looking statement in
this press release speaks only as of the date of this press
release. The Company undertakes no obligation to publicly update or
review any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by any applicable securities laws. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in Therapix
Biosciences Ltd.'s annual report on Form 20-F dated May 1, 2017 filed with the SEC, which is
available on the SEC's website, www.sec.gov.
For further information:
Investor Contact:
Josh Blacher
CFO, Therapix Biosciences
josh@therapixbio.com
Therapix Biosciences Ltd.
For further information: +972-3-616-7055
Media Contact:
Susan Forman
DGI
+1-212-825-3210
View original
content:http://www.prnewswire.com/news-releases/therapix-to-present-at-and-attend-investor-conferences-in-london-300550792.html
SOURCE Therapix Biosciences Ltd.